Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition

Anne Thompson

akstanwyck

More stories by Anne

‘Nosferatu’: How to Make a Robert Eggers Movie, with Help from Mel Brooks and Chris Columbus

In the Photorealistic

September 5 Director Tim Fehlbaum Didn

Time：2024-09-03 12:09

Recursion selected its lead drug, REC-994, using machine learning, but before installing this supercomputer at its Salt Lake City headquarters.Niki Chan Wylie for STAT

By Allison DeAngelis

Sept. 3, 2024

Biotech Startups and Venture Capital Reporter

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI drug developer.

The Salt Lake City company’s treatment is for cerebral cavernous malformation, or CCM, a potentially life-threatening condition that causes vessels in the brain to become enlarged and irregular, sometimes causing blood to leak into the brain or spinal cord.

Recursion’s oral drug, called REC-994, achieved the primary goal of a year-long, 62-person Phase 2 study, proving safe and tolerable for patients compared to a placebo, the company said in a press release.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe Log In Artificial intelligence, Clinical trials, STAT+ Submit a correction requestReprints

Allison DeAngelis
Biotech Startups and Venture Capital Reporter
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.